DGX Quest Diagnostics
- 148.955
- -0.0050.00%
Quest Diagnostics News
UBS Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $165
Barclays Maintains Quest Diagnostics(DGX.US) With Hold Rating, Maintains Target Price $154
Quest Diagnostics (DGX) Receives a Hold From Morgan Stanley
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX) and PDS Biotechnology (PDSB)
Quest Diagnostics Is Maintained at Hold by Truist Securities
Quest Diagnostics Analyst Ratings
Truist Financial Maintains Quest Diagnostics(DGX.US) With Hold Rating, Announces Target Price $165
Balancing Growth Prospects and Challenges: A Hold Recommendation for Quest Diagnostics
Jefferies Adjusts Price Target on Quest Diagnostics to $175 From $160
Baird Adjusts Price Target on Quest Diagnostics to $155 From $154, Maintains Neutral
Evercore Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $165
Quest Diagnostics: Hold Rating Affirmed Amid Balanced Risk/Reward Profile and Premium Valuation
Analysts Conflicted on These Healthcare Names: Quest Diagnostics (DGX), Astrana Health (ASTH) and Dexcom (DXCM)
Quest Diagnostics Analyst Ratings
Barclays Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $154
Barclays Remains a Hold on Quest Diagnostics (DGX)
Barclays Raises Quest Diagnostics' Price Target to $154 From $144, Maintains Equalweight Rating
JPMorgan Adjusts Price Target on Quest Diagnostics to $173 From $155, Maintains Neutral Rating
Quest Diagnostics: Strong Performance and Growth Trajectory Justify Buy Rating
Piper Sandler Adjusts Price Target on Quest Diagnostics to $150 From $145, Maintains Neutral Rating
Analysis
Price Target
No Data
No Data
